Skip to content

Enveric Biosciences

1 viewer · 30d

Total raised

$5.0M

+$5.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $5.0M
ROUNDS
1
INVESTORS
4
FOUNDED
N/A
HQ
Cambridge, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Enveric Biosciences is a clinical-stage biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders such as depression, anxiety, and addiction. Its compounds are designed to promote neuroplasticity without the hallucinogenic effects associated with classical psychedelics, so they can be prescribed and taken on an outpatient basis. Discovery runs through the company's proprietary Psybrary platform, which has generated a portfolio of protected novel chemical structures. Enveric has no approved products; its lead candidate EB-003 is advancing toward an IND filing with first-in-human trials planned for 2026.

What sets it apart

Designs neuroplastogens that engage psychedelic-adjacent receptor targets (EB-003 selectively engages both 5-HT2A and 5-HT1B) while removing the hallucinogenic effect, enabling a conventional take-home prescription model rather than supervised in-clinic dosing.

Funding history

1 round
Equity+1Apr 17, 2026
Form D
+$5.0M$5.0M total

Latest SEC filings

via EDGAR · CIK 0000890821
Form D · Apr 17, 2026View on EDGAR

Products

1 tracked

EB-003

Central nervous system drug candidate

Lead small-molecule neuroplastogen candidate, the first known compound designed to selectively engage both the 5-HT2A and 5-HT1B receptors. It is being advanced toward an FDA pre-IND meeting and IND submission, with first-in-human trials planned for 2026 in difficult-to-treat mental health disorders.

  • Dual 5-HT2A and 5-HT1B receptor engagement
  • Non-hallucinogenic neuroplastogen profile supported by recent preclinical data
  • Oral small molecule intended for a take-home prescription model
  • Advancing toward IND submission with first-in-human trials planned for 2026

Links

WebsiteLinkedInSEC EDGAR filings